Literature DB >> 26435990

Ethionamide: Unusual Cause of Hypothyroidism.

Ajay Raj Mallela1, Rohini Koya1, Shivashankara Kaniyoor Nagari2, Aswini Kumar Mohapatra3.   

Abstract

Multidrug-Resistant tuberculosis (MDR TB) is major health hazard to the people living in developing countries. As incidence rate of MDR TB has gone up, its therapy has become crucial. MDR TB therapy is known to cause multiple adverse effects however the data related to them is minimal. Hypothyroidism is one of the important adverse effects which usually manifests with vague symptoms and is frequently missed. We present a case of 24-year-old woman who was diagnosed to have MDR TB and started on ethionamide based regimen for same. After 6 months of therapy the patient had clinical symptoms suggestive of hypothyroidism, laboratory investigations confirmed it. As ethionamide is an integral component of MDR TB therapy it was continued and thyroxine replacement therapy was given with which she improved. Hypothyroidism completely resolved after 2 months of stoppage of MDR TB therapy suggesting the reversible aetiology of ethionamide.

Entities:  

Keywords:  Multidrug-resistant tuberculosis; Thyroid stimulating hormone

Year:  2015        PMID: 26435990      PMCID: PMC4576583          DOI: 10.7860/JCDR/2015/13531.6331

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  8 in total

1.  Ethionamide-induced hypothyroidism.

Authors:  Bikram S Dutta; G Hassan; Q Waseem; S Saheer; Abhijeet Singh
Journal:  Int J Tuberc Lung Dis       Date:  2012-01       Impact factor: 2.373

2.  Hypothyroidism due to ethionamide.

Authors:  Marie E McDonnell; Lewis E Braverman; John Bernardo
Journal:  N Engl J Med       Date:  2005-06-30       Impact factor: 91.245

3.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

4.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

Authors:  D Falzon; E Jaramillo; H J Schünemann; M Arentz; M Bauer; J Bayona; L Blanc; J A Caminero; C L Daley; C Duncombe; C Fitzpatrick; A Gebhard; H Getahun; M Henkens; T H Holtz; J Keravec; S Keshavjee; A J Khan; R Kulier; V Leimane; C Lienhardt; C Lu; A Mariandyshev; G B Migliori; F Mirzayev; C D Mitnick; P Nunn; G Nwagboniwe; O Oxlade; D Palmero; P Pavlinac; M I Quelapio; M C Raviglione; M L Rich; S Royce; S Rüsch-Gerdes; A Salakaia; R Sarin; D Sculier; F Varaine; M Vitoria; J L Walson; F Wares; K Weyer; R A White; M Zignol
Journal:  Eur Respir J       Date:  2011-08-04       Impact factor: 16.671

5.  High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho.

Authors:  H Satti; A Mafukidze; P L Jooste; M M McLaughlin; P E Farmer; K J Seung
Journal:  Int J Tuberc Lung Dis       Date:  2012-04       Impact factor: 2.373

6.  Ethionamide-induced goitrous hypothyroidism.

Authors:  D Drucker; M C Eggo; I E Salit; G N Burrow
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

7.  Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.

Authors:  Pauline Joseph; Vijaya Bhaskara Rao Desai; Nalini Sunder Mohan; Jemima Sheila Fredrick; Rajeswari Ramachandran; Balambal Raman; Fraser Wares; Ranjani Ramachandran; Aleyamma Thomas
Journal:  Indian J Med Res       Date:  2011-05       Impact factor: 2.375

8.  High rate of hypothyroidism in multidrug-resistant tuberculosis patients co-infected with HIV in Mumbai, India.

Authors:  Aristomo Andries; Petros Isaakidis; Mrinalini Das; Samsuddin Khan; Roma Paryani; Chitranjan Desai; Alpa Dalal; Homa Mansoor; Reena Verma; Dolorosa Fernandes; Giovanni Sotgiu; Giovanni B Migliori; Peter Saranchuk
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.